This CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). If approved, Reblozyl would be the first erythroid maturation agent approved in the EU, representing a new class of therapy for eligible patients. The safety and efficacy results provided in the application are from the pivotal Phase 3 MEDALIST and BELIEVE studies, evaluating the ability of Reblozyl to effectively address anemia associated with MDS and beta thalassemia, respectively.
“The positive CHMP opinion of Reblozyl is an important milestone for adult beta thalassemia patients in the EU who have limited treatment options to address anemia, a serious consequence of the disease,” said Maria Domenica Cappellini, M.D., Professor of Medicine, University of Milan, and lead investigator of the BELIEVE study. “Reblozyl has the potential to significantly decrease the number of red blood cell transfusions patients need.”
“This decision by the CHMP is an important step towards making this first-in-class therapy an option for eligible patients with anemia due to β-thalassaemia or myelodysplastic syndromes,” said Diane McDowell, M.D., vice president, Hematology Global Medical Affairs, Bristol Myers Squibb. “We, and our partners at Acceleron, look forward to the opportunity to make this treatment option available in the EU and are extremely appreciative of the patients, families and individuals who continue to help us progress important research in a range of serious diseases.”
Read the CHMP full opinion on Reblozyl HERE.